A Parisian Nanomedicine biotech is using it’s proprietary NanoXray technology to enhance radiotherapy. Now a candidate to treat Prostate cancer has received FDA approval for a phase I/II trial in the US.
Nanobiotix is seeking to develop NBTXR3 for patients with intermediate and high-risk prostate cancer, with the aim of providing effective tumor destruction and disease control.
As a spin-off of the State University of New York (SUNY), Nanobiotix was founded in 2003, but with it’s HQ in Paris and primary funding from European VCs. We also interviewed their CEO, Laurent Levy, back in April.
Since 1 in 7 men are diagnosed with prostate cancer and it is the second leading cause of cancer death in the US (according to the American Cancer Society), a potential enhancer of existing radiotherapeutics is a smart way to tackle the disease.
This is because radiation must first pass through healthy tissues before reaching the tumor target,